CRDL
Cardiol Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRDL
Cardiol Therapeutics Inc.
A clinical-stage biotechnology company that developing anti-inflammatory therapies for cardiovascular diseases
2265 Upper Middle Road East, Suite 602, Oakville, Ontario L6H 0G5
--
Cardiol Therapeutics Inc., founded on January 19, 2017 in Ontario, Canada, is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. The company's lead product, CardiolRx, a medicinal oral cannabidiol formulation, is conducting an outcome study of hospitalized patients who have tested positive for the COVID - 19 virus. This potential registration trial aims to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID patients with a prior history of CVD or risk factors, and to investigate the impact of CardiolRx as a key marker of inflammatory heart disease.
Company Financials
EPS
CRDL has released its 2025 Q3 earnings. EPS was reported at -0.09, versus the expected -0.0713114169579, missing expectations. The chart below visualizes how CRDL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
